Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 2Stomach Neoplasms 1Sarcoma, Synovial 1Platinum-Resistant Ovarian Carcinoma 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 24Paclitaxel 7Docetaxel 7Cyclophosphamide 7Carboplatin 7fludarabine 6Taxes 6Nivolumab 6Trastuzumab 5Magnetic Resonance Spectroscopy 5atezolizumab 4Specimen Handling 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Gemcitabine 4Fluorouracil 4Cisplatin 4tisotumab vedotin 3fludarabine phosphate 3Radiation 3Oxaliplatin 3Leucovorin 3Irinotecan 3Ipilimumab 3Gene Expression Profiling 3Drug Therapy 3Counseling 3Albumin-Bound Paclitaxel 3zimberelimab 2ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Immunotherapy, Adoptive × Gynecologic × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡